WestPark Capital Initiates Coverage On Enanta Pharma with Buy Rating, Announces Price Target of $24

Benzinga · 09/02/2025 11:26
WestPark Capital analyst Ed Arce initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Buy rating and announces Price Target of $24.